Abstract 295P
Background
Volumetric arc therapy (VMAT) with Simultaneous Integrated Boost (SIB) allows radiotherapy dose escalation to the region of involved nodes also reducing toxicity in node-positive patients of cervical cancer. Aim of this study was to evaluate the early outcome and acute toxicity with chemo-radiation usingVMAT with SIB in patients with locally advanced cervical cancer.
Methods
Thirty-three newly diagnosed cases of carcinoma cervix having Positron emission tomography (PET) positive pelvic/para-aortic nodes were included after obtaining a written informed consent. The complete clinical assessment and staging was performed. All patients were treated by VMAT with SIB technique to the dose of 50.4Gy to the primary site with draining nodes and 58.8Gy to PET positive nodes in 28 fractions followed by HDR brachytherapy boost of 7Gy in three fractions. Concurrent cisplatin at the dose of 40mg/m2 was administered on weekly basis during External beam radiotherapy. Acute toxicity was assessed according to the RTOG Acute Radiation Morbidity scoring criteria. Post treatment response was assessed by clinical examination and PET-CT /CECT scans at 3months.
Results
Median age was 55 years(range 35-70). The mean tumor size was 5.7cm (range 3.5-9) with 90% patients having disease more than 4cm. Median Standardized uptake value maximum in PET at primary tumor and LN was 17.3 and 8.7 respectively. Pelvic node only was seen in 23(69.6%) patients while Para-aortic node was involved in ten. Bladder and rectum invasion was seen in four and two patients respectively.Twenty-six (79%) patients received four or more cycles of concurrent Cisplatin. The median overall treatment time was 62 days. Response assessment at 3months showed complete response in 27 patients (82%), partial response in four while progressive disease in two patients. Maximum grade of toxicity at 3 months in skin, gastrointestinal, and hematological was grade I whereas one patient had grade III genitourinary toxicity. At last follow up, 30 patients were alive while three patients died; two deaths due to disease.
Conclusions
VMAT with SIB to involved nodes to higher doses results in effective early loco-regional control with acceptable acute toxicities.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
R. Mishra.
Funding
Institute of Eminence, Banaras Hindu University, Varanasi.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
321P - Epidemiology and survival analysis of epithelial ovarian cancer: Results from comprehensive care center in north India
Presenter: Amit Badola
Session: Poster Display
Resources:
Abstract
322P - Evaluation of chemotherapy response score as a prognostic factor in advanced epithelial ovarian cancer: A prospective single centre study
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
323P - Platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio as prognostic biomarkers in ovarian cancer among the Asian population: A meta-analysis
Presenter: Wikania Wira Wiguna I Gede
Session: Poster Display
Resources:
Abstract
324P - All-<italic>trans</italic> retinoic acid sensitizes ovarian cancer to niraparib by inhibiting ALDH1A1 activity
Presenter: Bingjie Mei
Session: Poster Display
Resources:
Abstract
325TiP - A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04)
Presenter: Myong Cheol Lim
Session: Poster Display
Resources:
Abstract
327TiP - A single arm phase II study of single agent pemetrexed in platinum resistant/refractory epithelial ovarian or primary peritoneal cancer
Presenter: Swasthik Parampalli
Session: Poster Display
Resources:
Abstract
337P - Demographic patterns and survival outcomes of patients with T and NK-cell lymphoma at the National Cancer Centre Singapore
Presenter: Mohamed Haniffa Bin Hasan Mohamed
Session: Poster Display
Resources:
Abstract
338P - Multicenter real-world study of advanced-stage non-nasal type NK/T cell lymphoma (NKTCL): Clinical features, treatment and prognosis
Presenter: Yuce Wei
Session: Poster Display
Resources:
Abstract
339P - A comparison of survival of patients with relapsed or refractory diffuse large B cell lymphoma undergoing allogeneic stem cell transplantation or receiving CAR-T therapy
Presenter: Kenta Hayashino
Session: Poster Display
Resources:
Abstract
340P - The role of CT scans and laboratory tests for surveillance in patients with diffuse large B cell lymphoma who achieved complete remission after first-line chemotherapy
Presenter: YU Yagi
Session: Poster Display
Resources:
Abstract